Acrivon Therapeutics Grants 160K Equity Units to Chief Business Officer
Acrivon Therapeutics, Inc.
Subscribe to track ACRV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Acrivon Therapeutics Grants 160K Equity Units to Chief Business Officer
Company: Acrivon Therapeutics, Inc. (ACRV)
Form: 4 | Filed: 2026-09-02
Significance: Low
Insider: Michaela Levin Title: Chief Business Officer | Relationship: Officer
Transaction Details: • Type: Grant (RSUs & Stock Options) • Common Stock / RSUs: 30,000 shares ($0.00) • Stock Options: 130,000 options (Exercise price: $2.09) • Direct Ownership After: 30,000 common shares / RSUs
Key Insight: Routine equity incentive grant consisting of 30,000 RSUs and 130,000 stock options subject to time-based vesting schedules.
Comprehensive Analysis
SEC Filing Analysis: Acrivon Therapeutics, Inc. (ACRV)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Chief Business Officer Michaela Levin was awarded 30,000 RSUs and 130,000 stock options as standard executive compensation.
- Market Impact: Neutral; routine compensation grant with minimal immediate dilutive impact.
Company Information
| Field | Value |
|---|---|
| Company | Acrivon Therapeutics, Inc. |
| Ticker Symbol | ACRV |
| CIK | 0001781174 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Michaela Levin |
| CIK | 0002151012 |
| Title/Position | Chief Business Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2026-08-31 |
| Transaction Code | A (Grant / Award) |
| Security Type | Common Stock (RSUs) / Options |
| Shares Involved | 30,000 RSUs (+ 130,000 Options) |
| Price Per Share | $0.00 (Options exercise at $2.09) |
| Total Value | $0.00 (Grant) |
| Shares Owned After | 30,000 (Non-derivative) |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0.00 |
| % of Market Cap | 0.00% |
| Shares Transacted | 30,000 (160,000 total underlying) |
| % of Shares Outstanding | 0.07% (0.37% fully diluted) |
| Post-Transaction Ownership | 30,000 shares (0.07% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: Acrivon operates as a micro-cap biopharmaceutical company with a ~$90M market capitalization.
- Dilution Impact: The grant represents ~0.07% of outstanding shares in RSUs and up to 0.37% including option incentives, posing negligible immediate dilution.
- Ownership Concentration: Insider equity stake remains modest and aligned with standard early-stage biotech compensation structures.
Market Impact Analysis
- Direction: Neutral
- Reasoning: Standard equity grant to executive management does not represent open-market buying or selling activity.
- Volume & Sentiment: Minimal to no impact on trading volume or overall sentiment.
Additional Context
- Vesting Terms: The 30,000 RSUs vest in full on September 1, 2027. The 130,000 stock options vest 25% on September 1, 2027, with the remainder vesting in 36 equal monthly installments.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.